ADHD
Study register · detail Systematic Review · ADHD · 2023

Cannabis Use in Patients With Attention Deficit Hyperactivity Disorder- A Benefit or a Curse: A Systematic Review

Unclear GRADE High 2 citations
SampleSystematische Review
DurationPublications from the previous…
EndpointADHD symptoms & cannabis use…
Blindingunklar
DesignSystematic Review
Key finding

The systematic review identifies mixed findings on cannabis use in ADHD patients; a conclusive assessment of benefit or harm is not made.

Summary

Systematic review on cannabis in ADHD (search period up to 2023); heterogeneous data situation with individual observational studies and case reports. Authors conclude: insufficient evidence, benefit-risk ratio unclear, RCTs lacking. No robust efficacy data for ADHD.

P
PopulationAdults and adolescents with attention-deficit/hyperactivity disorder (ADHD), pooled from 20 studies (2 non-RCTs, 1 cross-sectional study, 1 meta-analysis, 16 observational cohorts)
I
InterventionCannabis use (various forms of application and cannabinoid compositions)
O
OutcomeNarrative synthesis on associations between cannabis use and ADHD symptomatology as well as executive function impairments — no quantitative pooled effects reported
Confidence in the evidence
High

The highest of four GRADE levels, the effect estimate is very reliable.

Quality profile
Sample size
Blinding
Effect size
Citations / year
Authors
Dhamija D, Bello A O, Khan A A et al.
DOI 10.7759/cureus.40969
Design: Systematic Review
Share
Abstract
Cannabis is frequently used by people who self-medicate for the signs of mental health conditions. Attention-deficit/hyperactivity disorder (ADHD), a neurodevelopmental illness, has been linked to increased cannabis use. However, compared to other mental disorders, cannabis use by people with ADHD has received much less research. The main goal of this systematic review was to understand the nature of the relationships between cannabis use and ADHD symptoms. We used Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines to conduct the systematic review. We included papers published within the previous ten years from online searches on PubMed, PubMed Central (PMC), Google Scholar, and ScienceDirect until January 1st, 2023. The inclusion-exclusion criteria led to the initial selection of 136 studies. We selected twenty research articles after screening and assessing them using quality assessment techniques. These articles included two non-randomized control trials, one cross-sectional study, one meta-analysis, and sixteen observational cohorts. It can be advantageous for people with ADHD and their medical professionals to understand better how ADHD patients use cannabis and its potential risks and advantages on cannabis use disorder, ADHD symptoms, and executive dysfunction. This article further emphasizes the necessity of thorough research to comprehend cannabis use in ADHD patients.

The impediment to action advances action. — Marcus Aurelius